Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

X
Trial Profile

MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Entrectinib (Primary) ; Inavolisib (Primary) ; Ipatasertib (Primary) ; Pertuzumab/trastuzumab (Primary) ; Trastuzumab emtansine (Primary) ; Tucatinib (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Acronyms myTACTIC
  • Sponsors Genentech
  • Most Recent Events

    • 05 Mar 2024 Status changed from active, no longer recruiting to completed.
    • 18 Dec 2023 Planned End Date changed from 28 Dec 2023 to 27 Feb 2024.
    • 06 Jun 2023 Results assessing the efficacy and safety of arm E from MyTACTIC presented at the 59th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top